Clinical Benefits of CBD in studies and research includes the following publications;
- Neurological Aspects of Medical Use of Cannabidiol (http://www.eurekaselect.com/151582/article) –
Laboratory and clinical studies on the potential role of CBD in Parkinson’s disease (PD), Alzheimer’s disease (AD), multiple sclerosis (MS), Huntington’s disease (HD), amyotrophic lateral sclerosis ALS), cerebral ischemia, were examined. Conclusion: Pre-clinical evidence largely shows that CBD can produce beneficial effects in AD, PD and MS patients, but its employment for these disorders needs further confirmation from well designed clinical studies. CBD pre-clinical demonstration of antiepileptic activity is supported by recent clinical studies in human epileptic subjects resistant to standard antiepileptic drugs showing its potential use in children and young adults affected by refractory epilepsy. Evidence for use of CBD in PD is still not supported by sufficient data whereas only a few studies including a small number of patients are available.
2. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia (https://www.nature.com/articles/tp201215)
Their results provide evidence that the non-cannabimimetic constituent of marijuana, cannabidiol, exerts clinically relevant antipsychotic effects that are associated with marked tolerability and safety, when compared with current medications.
3. Cannabinoids for pediatric epilepsy? Up in smoke or real science? (http://tp.amegroups.com/article/view/8122/8915)
Controlled trials of various pharmaceutical cannabis products for the treatment of multiple sclerosis (specifically the painful spasms of MS) began in the early 2000s. Initial studies did use a variety of preparations. This culminated in a series of high quality placebo-controlled trials with Sativex (a 50:50 mixture of THC and CBD) from 2006 to 2011. These trials demonstrated a statistically significant benefit of Sativex in the management of painful MS spasms, resulting in the marketing of this agent in England and many other countries (not including the United States).
4. Cannabinoids in the Treatment of Neurological Disorders (https://link.springer.com/article/10.1007/s13311-015-0388-0)
We are pleased to have gathered many of the world’s experts together on the basic biology of cannabinoids, as well as their potential role in treating neurologic and psychiatric disorders. Dr. Di Marzo briefly introduces the endocannabinoid system. Dr. Whalley explains the molecular pharmacology of cannabidiol in neurological disorders, while Dr. Justinova discusses the biology of endocannabinoids. Dr. Gloss reviews the currently available cannabinoid products and the challenges facing our interpretation of the data associated with their clinical use. Drs Sachs, McGlade, and Yurgelun-Todd provide a general overview of the safety and toxicity of cannabinoids. Dr. Notcott reviews the clinical use of cannabinoids for the treatment of multiple sclerosis. Drs Stephens, Arjmand, and Shabani review the use of cannabinoids in the treatment of tremors. Drs Fernandez-Ruiz, Martinez-Orgado, and Moro review the use of cannabinoids in the treatment of neurodegenerative disorders and stroke. Dr. Hohmann reviews the use of cannabinoids in pain treatment. Drs Jutras-Aswad and Hurd review the use of cannabinoids in drug abuse treatment. Drs Blessing, Steenkamp, Marmar, and McCabe review cannabinoid use to treat anxiety. Dr. Goff reviews the risks and benefits of utilizing CBD as a treatment for schizophrenia. Drs Maccarrone and Chakrabarti explore the therapeutic potential of cannabinoids in treating autism. Dr. Koppel reviews the use of cannabinoids in treatment for dyskinesia, dystonia, and tics. Drs Rosenberg, Tsien, Whalley, and Devinsky review the use of cannabinoids in epilepsy.